

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

## Larotrectinib for treating advanced solid tumours with NTRK fusions [ID1299]

## Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Bayer (Larotrectinib)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Sick Children</li> <li>• Anthony Pilcher Bone Cancer Trust</li> <li>• Black Health Agency</li> <li>• Bob Champion Cancer Trust</li> <li>• Bowel Cancer UK</li> <li>• Breast Cancer Care</li> <li>• Breast Cancer Now</li> <li>• Breast Cancer UK</li> <li>• British Lung Foundation</li> <li>• British Skin Foundation</li> <li>• Butterfly Thyroid Cancer Trust</li> <li>• Cancer 52</li> <li>• Cancer Black Care</li> <li>• Cancer Equality</li> <li>• Cancer Laryngectomy Trust</li> <li>• Changing Faces</li> <li>• Childhood Cancer Parents Alliance</li> <li>• Children's Cancer and Leukaemia Group</li> <li>• Children with Cancer</li> <li>• CLIC Sargent</li> <li>• Genetic Alliance UK</li> <li>• Get-A-Head</li> <li>• Haven</li> <li>• HAWC</li> <li>• Helen Rollason Cancer Charity</li> <li>• Independent Cancer Patients Voice</li> <li>• Kidney Cancer Support Network</li> <li>• Kidney Cancer UK</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Let's Face It</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Allied Health Professionals Federation</li> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Association of Renal Industries</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Health and Safety Executive</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> <li>• Welsh Kidney Patients Association</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Against Breast Cancer</li> <li>• Bone Cancer Research Trust</li> <li>• Bone Research Society</li> <li>• Breast Cancer Hope</li> <li>• Breast Cancer Research Trust</li> <li>• British Society for Dermatological Surgery</li> <li>• Cochrane Breast Cancer Group</li> </ul>

Matrix for the technology appraisal of larotrectinib for treating advanced solid tumours with NTRK fusions ID1299 Issue date: March 2019

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Macmillan Cancer Support</li> <li>• Maggie’s Centres</li> <li>• Marie Curie</li> <li>• Mouth Cancer Foundation</li> <li>• Muslim Council of Britain</li> <li>• National Association Of Laryngectomee Clubs</li> <li>• National Children’s Bureau</li> <li>• National Kidney Federation</li> <li>• Orchid – Fighting Male Cancer</li> <li>• Prostate Cancer UK</li> <li>• Prostate Help Association</li> <li>• Roy Castle Lung Cancer Foundation</li> <li>• Sarcoma UK</li> <li>• Solving Kid’s Cancer</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Swallows Head and Neck Cancer Support Group</li> <li>• Teenage Cancer Trust</li> <li>• Tenovus Cancer Care</li> <li>• The Royal Marsden Cancer Charity</li> <li>• Together for Short Lives</li> <li>• UK Lung Cancer Coalition</li> <li>• Women’s Health Concern</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Anaesthetists</li> <li>• Association of Cancer Physicians</li> <li>• Association of Respiratory Nurse Specialists</li> <li>• Association of Surgeons of Great Britain and Ireland</li> <li>• British Association of Dermatologists</li> <li>• British Association of Endocrine and Thyroid Surgeons</li> <li>• British Association of Skin Cancer Specialist Nurses</li> <li>• British Association of Surgical Oncology</li> <li>• British Association of Urological Surgeons</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> </ul>	<ul style="list-style-type: none"> <li>• Cochrane Childhood Cancer Group</li> <li>• Cochrane Lung Cancer Group</li> <li>• Cochrane Prostatic Diseases Urologic Cancers Group</li> <li>• Cochrane Skin Group</li> <li>• Genomics England</li> <li>• Head and Neck Cancer Research Trust</li> <li>• Institute of Cancer Research</li> <li>• MRC Clinical Trials Unit</li> <li>• Myfanwy Townsend Melanoma Research Fund</li> <li>• National Cancer Research Institute</li> <li>• National Cancer Research Network</li> <li>• National Institute for Health Research</li> <li>• Ovarian &amp; Prostate Cancer Research Trust</li> <li>• Pro Cancer Research Fund</li> <li>• Prostate Cancer Research Centre</li> <li>• Research Institute for the Care of Older People</li> <li>• Skin Cancer Research Fund</li> <li>• Skin Treatment &amp; Research Trust</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Institute of Musculoskeletal Medicine</li> <li>• British Institute of Radiology</li> <li>• British Orthopaedic Association</li> <li>• British Orthopaedic Oncology Society</li> <li>• British Prostate Group</li> <li>• British Psychosocial Oncology Society</li> <li>• British Renal Society</li> <li>• British Sarcoma Group</li> <li>• British Society for Dermatological Surgery</li> <li>• British Society of Skeletal Radiologists</li> <li>• British Society of Urogenital Radiology</li> <li>• British Thoracic Oncology Group</li> <li>• British Thoracic Society</li> <li>• British Thyroid Association</li> <li>• British Uro-oncology Group</li> <li>• Cancer Research UK</li> <li>• Children's Cancer &amp; Leukaemia Group</li> <li>• Melanoma Focus</li> <li>• National Lung Cancer Forum for Nurses</li> <li>• Pelican Cancer Foundation</li> <li>• Primary Care Dermatology Society</li> <li>• Renal Association</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Society and College of Radiographers</li> <li>• UK Health Forum</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK Genetic Testing Network</li> <li>• UK Oncology Nursing Society</li> <li>• UK Renal Pharmacy Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS North East Hampshire and</li> </ul>	

Matrix for the technology appraisal of larotrectinib for treating advanced solid tumours with NTRK fusions  
ID1299 Issue date: March 2019

Consultees	Commentators (no right to submit or appeal)
Farnham CCG <ul style="list-style-type: none"> <li>• NHS Swale CCG</li> <li>• Welsh Government</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

## Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.